Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Dedalus, de totale ICT-integratie voor Covid-19 pandemie
Volgen
Het bedrijf maakte afgelopen tijd enorme koerssprong... Dedalus for Covid-19 Over 1.000.000 healthcare workers in more than 30 Countries in the world are using Dedalus applications while taking care of hundreds of millions of patients from China to USA, from UK to South Africa and Latin America. The entire world is facing the emergency of a pandemic which we would have never wanted to happen, but which already affected dozens of Countries. All Governments are gradually adopting ever more restrictive rules, with the aim of reducing the spread of the virus; it is fundamental to interact with citizens in the quickest and easiest way, as well as to organize to most efficient methods to classify citizens showing symptoms, in order to be able to speed up and manage in an orderly way the testing phase and the allocation of the various activities, bringing the patient in the right place on time, avoiding panic amongst the public and preventing incorrect use of healthcare resources. It is therefore necessary to have a system available as soon as possible to better manage all the initial stages of the pandemic process. We need to make it available and to operate in an extraordinary way to manage a high-risk pandemic phase. In this spirit, Dedalus reacted and went beyond. In record time, we created a system to check the spread of the virus. This system is going around the world for the benefit of patients and healthcare systems; together with our international partners we are offering it to several countries and local organizations. We are aware that this is a race against time, but we are ready to activate it in few days for those who will demand it. The system is totally integrated and considers any detail: from the initial stage, in order to reduce contagion, to the management of all the steps preceding the possible hospitalization, including the test-cycle management. We already faced all the various issues, that means, not only functionalities but even the dynamics related to: installation, training of the staff that will use it, how to make it user-friendly for the citizen, modalities for large-scale communication and the several particular cases which must be managed. Here below you can watch two videos which explain the system in full and the component dedicated to the citizen/patient.
Vandaag is Dedalus 17% gestegen! Het aandeel is goed voor een aanhoudende groei komende maanden. MB
45% up. Hou het in de gaten, en verdiep je er eens in...
Le Groupe Dedalus Engagé et Solidaire dans la lutte contre la propagation du Covid-19 L’application Co4Covid-19 de Dedalus propose dans le contexte de crise Covid-19, une prise en charge complète du parcours patient, du diagnostic au suivi ambulatoire du patient. Gratuite, cette application s’adresse aux citoyens, aux établissements de santé et aux institutions et permet : Répondre aux questions de la population Pré-dépister la population, détecter d’éventuels citoyens positifs Informer les citoyens de la situation, des risques et de la conduite à tenir Suivre la propagation de la maladie en temps réel Agir rapidement pour ralentir la propagation du viruswww.youtube.com/watch?v=z87n6FNKrq8&a...
News | April 28, 2020 AI Accelerating Drug Discovery To Fight COVID-19 Deep learning, drug docking and molecular dynamics simulations identify ways to shut down virus Researchers are running a global race to discover a vaccine, drug or combination of treatments that can disrupt the SARS-CoV-2 virus, which causes the COVID-19 disease, and prevent widespread deaths. Major efforts are underway to screen every possible molecule that might interact with the virus -- and the proteins that control its behavior -- to disrupt its activity. In addition to working faster, computational scientists are working smarter, combining artificial intelligence with physics-based drug docking and molecular dynamics simulations to rapidly look at the most promising molecules. A project using some of the most powerful supercomputers on the planet -- including the National Science Foundation-funded Frontera and Longhorn supercomputers at the Texas Advanced Computing Center and Comet at the San Diego Supercomputer Center -- is running millions of simulations, training a machine learning system to identify the factors that might make a molecule a good candidate, and doing explorations of the most promising results. "The discovery of effective therapeutics to mitigate the current COVID-19 crisis is critical for the rapid recovery of the global economy," says Ed Walker, a program director in NSF's Office of Advanced Cyberinfrastructure. "NSF-funded instruments such as Frontera and Comet provide important computational capabilities and human expertise to support multi-institution efforts harnessing our nation's research capabilities." The project complements epidemiological and genetic research efforts supported by TACC, which are enabling more than 30 teams to undertake research that would not otherwise be achievable in the timeframe this crisis requires. Source: National Science Foundation (NSF)
De zin en onzin van testen op Covid-19. Wat moet je doen en niet doen? Steengoed artikel van Bruce Y Lee van Forbes. Het is duidelijk dat er veel meer coördinatie en automatisering nodig is.1. How well are the tests really performing? What decisions are being made based on the test results? Coronavirus testing continues at the ProHealth testing centers in Jericho, New York on April 22, ... [+] Simply telling people that you’ve taken the SAT more often than anyone else is not going to get you admitted into the college of your choice. In a similar vein, when it comes to diagnostic tests, quantity does not trump quality, so to speak. Even though a number of different COVID-19 coronavirus tests may be on the market, it’s not yet completely clear how accurate each of these tests may be or how many of the tests cross the threshold of being reasonably accurate. If you want to put together a Broadway musical or a professional football team, you don’t just get as many people as possible. To help more tests reach the market, the U.S. Food and Drug Administration (FDA) has relaxed regulatory requirements. So it makes sense that there are now more different tests on the market. However, there are two sides to the coin. The trouble with relaxing requirements is that a lot more questionable stuff then may leak in as well, meaning that you have to do a lot more weeding out later. Just because a COVID-19 coronavirus test is on the market now, doesn’t mean that it is necessarily reliable or accurate. With any diagnostic test, you want to know these key measures: Sensitivity This is not how well the test empathizes with your problems or says, “things must be hard for you.” Instead, it is the probability that the test will be positive if you are actually infected with the virus. In other words, how well can the test detect the presence of a disease? The following formula calculates a test’s sensitivity: the number of true positives (TP) divided by the sum of the numbers of true positives (TP) plus false negatives (FN). Basically, the formula comes out to TP/(TP+FN). A TP is when the test result comes back positive and you actually are infected, meaning that the test result was correct. A FN is when the test result is incorrectly negative, even though you are infected. A low sensitivity would mean that many cases of infections will be missed. This is clearly not a good thing. An example of a low sensitivity test is using a person’s Tinder profile alone to determine if he or she is indeed a good lifetime partner. Specificity If you don’t have a COVID-19 coronavirus infection, what is the probability that the test will actually be negative? In other words, how well can the test confirm that you don’t have a given disease? This is what test specificity measures. A true negative is when the test is negative and no infection is present. A false positive is when the test is positive but there is really no infection. Thus, specificity equals the number of true negatives divided by the number of true negatives plus false positives: TN/(TN+FP). A low specificity would mean that many people will get positive tests when they aren’t actually infected. This can lead to a lot of people being isolated and worrying unnecessarily. This ain’t good either. An analogy would be relying on someone to tell you that he or she is a psychopath. Yes, if someone tells you on a first date that he or she is a psychopath then there’s probably a good chance that it’s true. “Being sort of a psychopath” is not something that people tend to joke about on a first date. However, it’s probably not a good idea to include “hasn’t openly admitted to being a psychopath” as one of the three main qualities that you are looking for in an ideal mate. Positive Predictive Value (PPV) Are you positive that the positive test result is correct? The PPV measures the probability that you actually have a COVID-19 coronavirus infection if a test result comes back positive. The formula for the PPV of test is the number of true positives divided by the number of true positives plus false positives: TP/(TP+FP). A low PPV means that many people will think that they are infected when they aren’t. An example of a test with a very low PPV is assuming that all people of a certain race are such and such. Sure, some people with that racial background may resemble the description. But most people don’t really match stereotypes. Negative predictive values (NPV) If you get a negative test, what is the probability that you really don’t have a COVID-19 coronavirus infection? The NPV measure this and equals the number of true negatives divided by the number of true negatives plus false negatives: TN/(TN+FN). A low NPV means that many people will get false assurances that they are not infected. This could lead to people not getting appropriate care in time and unknowingly spreading the virus to others. It will be important for the federal government to install some way of tracking the performance of different tests throughout the pandemic and reporting these performance measures to the public. Otherwise, different tests may yield very different results, leading to a comparing apples to oranges to who-knows-what-is-this-even-fruit situation.
2. How many people who want testing are actually getting testing? You don’t comfort your friend who is fretting over being single by telling him or her the total number of marriages that are occurring in the country. You don’t tell someone who is short on money about all the money that other people have. So declaring the total number of tests performed is not really going to assuage someone who is worried about COVID-19 coronavirus tests not being available. Instead, you want to offer statistics on the likelihood that the person will get what he or she wants. In other words, what are the chances of a person’s wishes or demands being fulfilled? That’s why there are measures of demand fulfillment such as: • Test availability: This is the percentage of people who want to get tested who actually end up getting tested. It is calculated by dividing the number of times people get tested by the number of times people want tests. You want this as close to 100% as possible. • Missed testing opportunities: This is the total number of times someone wanted a test but couldn’t get it. Of course, the higher this number goes, the worse the program. • Time-to-testing: Timing is important. If you order a pizza and get it delivered two years later, technically pizza availability was 100%. Technically, no missed pizza delivery opportunities occurred. But this may not leave you happy unless you’re planning your meals two years in advance. Time-to-testing is the amount of time that elapses from when you first want a test to when you actually get it. • Time-to-results: Testing is not like sex. Simply getting it is not enough. You also want to know the results, unless you happen to just want the experience of a cotton swab being shoved up your nose. Results need to return as soon as possible so that you and your doctor can make key decisions.
3. How much of the country are you really covering with testing? Who is getting tested and who isn’t? • Local residents Burnetta Kinsey (C) and Zina Parker (R) fill out paperwork at a mobile COVID-19 ... [+] • What if Google Maps only told you the total number of roads in the U.S or Tinder the total number of single people in your city? What if a news report just stated that one million killer rabbits wearing capes have invaded the country without giving a sense of where they actually are? As anyone who’s been in real estate knows, location matters. • That’s why seeing detailed maps that show testing coverage (i.e., what percentage of the population has gotten tested) would be helpful. Or at least a breakdown of all the previously mentioned testing measures by location and key socio-demographic groups. • After all, total numbers can hide the actual distribution of testing. There may be over 1.6 million sailboats in the U.S. but some people may have more than one, which decreases “sailboat coverage.” Similarly, the White House staff may be tested for the COVID-19 coronavirus every day adding to the total, but you may not be. Lopsided testing isn’t going to stop the spread of the virus. Unlike people, the virus does not discriminate. Even when the virus stops spreading among your close circles of friends and colleagues, as long as it is spreading somewhere, it is still spreading. • Ultimately, testing should be just one component of a coordinated response. Simply focusing on testing would be like going to a college where no teaching is done, only testing. Therefore, it will be important to know exactly how the COVID-19 coronavirus test results are being used, how they are guiding decision making, and how the results are being communicated to others. The pandemic isn’t an Olympic competition in which the goal is just have more of something than other countries, whether it is points or medals. Instead, public health responses are complex systems that require a systems approach of different measures to track progress or the lack thereof. • Follow me on Twitter or LinkedIn. Check out my website. • • Bruce Y. Lee
Alabama, North Dakota And South Carolina To Debut Apple And Google’s Covid-19 Contact Tracing Rachel Sandler Rachel SandlerForbes Staff Business I cover breaking news. TOPLINE Apple and Google released software on Wednesday that will allow public health agencies around the world to build their own apps to track who may have been exposed to Covid-19 using bluetooth signals, with Alabama, North Dakota and South Carolina the first U.S. states to sign on. Apple Affordable Housing Pledge In this June 3, 2019, file photo Apple CEO Tim Cook speaks at the Apple Worldwide Developers ... [+] AP Photo/Jeff Chiu, File KEY FACTS Apple and Google won’t build apps themselves, but have instead released the underlying technology that allows public health authorities to create their own contact tracing apps to download in the Apple Store or Google Play Store. Alabama, North Dakota and South Carolina are the first U.S. states to commit to using Apple and Google’s technology, along with 22 countries, including Ireland, Germany, Italy and the Netherlands. The Apple and Google contact tracing system will use bluetooth signals to exchange anonymous “keys” between phones that are in close proximity with each other; if someone is later diagnosed with Covid-19, they can enter their positive test result into an app and alert all the other phones that were near that “key” recently. The app has stringent privacy measures in place, such as not using location data and storing data on user devices rather than a centralized database overseen by a government authority—but some states and countries, such as the U.K., have complained that those measures make the app less effective. Crucial quote “North Dakota is excited to be among the first states in the nation to utilize the exposure notification technology built by Apple and Google to help keep our citizens safe,” Gov. Doug Burgum said in a statement. “As we respond to this unprecedented public health emergency, we invite other states to join us in leveraging smartphone technologies to strengthen existing contact tracing efforts, which are critical to getting communities and economies back up and running.” key background Public health experts say identifying and isolating infected people and their contacts will be necessary as countries begin to reopen their economies, though some say that while technology can help with the process, it is no substitute for hiring thousands of contract tracers, humans who are trained to track down and notify people who have been potentially exposed. The Johns Hopkins Center for Health Security estimates that the US needs to hire roughly 100,000 human contact tracers to be effective. news peg Other countries have opted to launch their own contact tracing apps without using Google and Apple’s technology, including China, India, Australia and Israel. Only China and India have mandated citizens use the app, which has led to widespread use, but those apps have still been scrutinized for privacy practices. Utah, too, has built its own contact tracing app that uses GPS location data, unlike Apple and Google. what to watch out for Adoption will be a challenge: Oxford University researchers say contact tracing apps have to be downloaded by 60% of the population in order to be effective, and it remains to be seen if Apple/Google’s effort will get that much buy-in. Full coverage and live updates on the Coronavirus
Dedalus afgelopen jaar zo'n kleine 200% gestegen. Staat nu op ca 0,8. Het Franse medisch software bedrijf was vanaf begin Bergamo ingeschakeld en heeft een enorme expertise opgebouwd in hoe staten / ziekenhuizen / bedrijven Corona- besmettingen kunnen tegengaan en indammen; cyberbeveiliging en begroting, kortom het hele ICT-plaatje. Ik zeg het nog maar even: ik heb nu al een rendement van 60% en het blijft hier niet bij.
MisterBlues schreef op 25 juni 2020 11:02 :
Dedalus afgelopen jaar zo'n kleine 200% gestegen. Staat nu op ca 0,8.
Het Franse medisch software bedrijf was vanaf begin Bergamo ingeschakeld en heeft een enorme expertise opgebouwd in hoe staten / ziekenhuizen / bedrijven Corona- besmettingen kunnen tegengaan en indammen; cyberbeveiliging en begroting, kortom het hele ICT-plaatje.
Ik zeg het nog maar even: ik heb nu al een rendement van 60% en het blijft hier niet bij.
Dadalus overgenomen op 0,8 door: Agfa Health Care IT solutions Agfa HealthCare is a division of the Agfa-Gevaert Group which is headquartered in Mortsel, Belgium and traded on Euronext Brussels (AGFB). COVID-19 specific configurations As a healthcare IT partner, we are deeply committed to support our clients during the COVID-19 crisis. Around the globe we are setting up COVID-19 specific configurations. By sharing the customer cases we encounter and the configurations we’re setting up, we hope to be of help. 1 – COVID-19 specific priority worklists 2 – Faster reporting with COVID-19 drop-down menus and text macros 3 – Remote and home reporting 4 – COVID-19 hanging protocols 5 – Supporting triage of high-risk patients 6 – Real-time collaboration across quarantine-lines 7 – Balance the load – Image sharing across hospital networks and regions 8 – Adding COVID-19 specific terminology to the speech recognition lexicon 9 – Business Intelligence: using data to better measure, understand, predict 10 – eLearning: 24/7 access to key knowledge Partner configuration: – MediReport COVID-19 Update Collaboration – XERO Viewer & Microsoft Teams integration – Dell Technologies, Barco, and Agfa HealthCare are teaming together Laatste bericht.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
887,44
+0,99%
EUR/USD
1,0762
+0,34%
FTSE 100
8.213,49
+0,51%
Germany40^
18.017,10
+0,67%
Gold spot
2.301,75
0,00%
NY-Nasdaq Composite
16.156,33
+1,99%
Stijgers
Dalers